Welcome to our dedicated page for Lifemd SEC filings (Ticker: LFMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to LifeMD, Inc. (Nasdaq: LFMD) SEC filings, offering detailed insight into the company’s virtual primary care and pharmacy operations. As a U.S. public company, LifeMD files annual reports on Form 10‑K, quarterly reports on Form 10‑Q, and current reports on Form 8‑K, along with other required documents. These filings describe its telehealth platform, pharmacy and compounding pharmacy activities, clinical programs across more than 200 conditions, and its evolution into a pure-play virtual care and pharmacy business following the divestiture of its majority interest in WorkSimpli Software LLC.
Through LifeMD’s 10‑K and 10‑Q reports, readers can review segment information, revenue composition, operating expenses, and risk factors associated with telehealth, pharmacy services, regulatory compliance, and collaborations with pharmaceutical manufacturers. The company’s filings also discuss its 50-state affiliated medical group, proprietary digital care platform, and affiliated pharmacy infrastructure, providing context on how its virtual care model is structured.
LifeMD’s Form 8‑K filings capture material events such as the sale of its majority stake in WorkSimpli, the establishment of a senior secured revolving credit facility with Citizens Bank, N.A., rescheduling of earnings releases, and the announcement of quarterly financial results. These current reports may also include press releases as exhibits, giving additional narrative detail on strategic transactions, capital structure decisions, and operational milestones.
The company has also filed a Form 12b‑25 (NT 10‑Q) to notify the SEC of a late quarterly filing due to the need for additional time to correct errors related to over-recognition of revenue in prior periods. In that notification, LifeMD stated that the adjustments would not affect its cash flow or cash position and that it was evaluating potential impacts on internal control over financial reporting.
On Stock Titan, LifeMD’s filings are updated in near real time as they are posted to the SEC’s EDGAR system. AI-powered tools summarize lengthy documents such as 10‑K and 10‑Q reports, highlight key changes across periods, and surface important disclosures related to revenue recognition, segment reporting, credit facilities, preferred stock dividends, and significant transactions. Users can also review Form 4 and other ownership filings to track insider transactions and equity awards, with AI-generated explanations that clarify the nature of each transaction.
By combining raw SEC documents with AI-driven summaries and comparisons, this page helps investors, analysts, and researchers quickly understand LifeMD’s regulatory disclosures, financial reporting, and governance developments without manually parsing every filing.
LifeMD, Inc. (LFMD) director Calum Archibald MacRae filed a Form 4 disclosing a non‑derivative grant of 22,365 restricted shares on 10/02/2025. The filing shows 38,865 total shares beneficially owned by the reporting person after the transaction. The restricted shares have a vesting condition: they vest on 06/01/2026. The transaction was reported on 10/06/2025 with a reported price of $0, consistent with a grant rather than an open‑market purchase.
LifeMD director Roberto Simon received 22,365 restricted stock units on 10/02/2025, increasing his beneficial ownership to 183,175 shares. The Form 4 shows the units were granted at a $0 price and are recorded as non‑derivative common stock awards.
The filing specifies the granted awards are restricted stock units that vest on